
Confo Therapeutics reports promising preclinical results for PBH drug candidate CFTX-2034, advancing toward clinical trials.
Confo Therapeutics announced encouraging preclinical data for CFTX-2034, a novel antibody targeting post-bariatric hypoglycemia (PBH), a condition with no approved treatments. The data showed CFTX-2034 effectively controls insulin and GLP-1 secretion...


